The present disclosure comprises a device and accompanying method for determining the presence or absence of Methicillin-resistant Staphylococcus aureus in a sample. The disclosure includes the following elements: (1) a lateral flow strip for microfluidic manipulation of a sample; (2) a cassette device for containing the lateral flow strip and enabling interface with a detection device; (3) a cassette handler; (4) a luminous reagent delivery device; and (5) an electromagnetic radiation detection device capable of converting chemiluminescent radiation from the lateral flow strip into an output for a user.

The claimed invention relates to mobile computing monitoring of health statistics using chemically synthesized conjugate markers providing highly specific details of personal health states. Using portable computing and communications devices, commonly known as ‘smartphones’, personal health and wellness information is gathered from chemical markers and reported to the user. Chemical markers include chemicals which undergo a measurable color change when combined with body fluids such as saliva. Health information derived from chemical markers may be optically collected, locally reported and widely broadcast over a ‘cloud based’ internet data distribution system.

Biomarkers for abnormal kidney function, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV, and methods for their use in assessing abnormal kidney function are disclosed herein.

The disclosure is directed to methods and kits for detecting neutralizing antibodies against a coronavirus (e.g., SARS-CoV-2) in a sample, such as a plasma sample or pooled plasma composition. The methods utilize a panel of SARS-CoV-2 neutralizing antibodies as a positive control. The kit may be a rapid detection kit that measures neutralizing antibodies using the provided methods.

Disclosed are a kit for testing myocardial infarction rapidly and a preparation method and use thereof. The kit comprises a strip capable of detecting three markers, namely, human myeloperoxidase (MPO), heart-fatty acid binding protein (FABP3) and cardiac troponin I(cTnI) simultaneously. The strip comprises a sample pad, a conjugate pad, a chromatographic membrane coated with three test lines and a quality control line, and a sample absorption pad. Antibodies of the three markers are all marked on the conjugate pad. The chromatographic membrane has three test lines formed by coating paired antibodies of the three markers respectively, the paired antibodies of the three markers being able to specifically combine with the three markers, respectively. The kit has advantages such as convenient operation, rapid response, high sensitivity and high specificity, point of care test, and economical and practical etc.

Lanthanide chelate lipid nanoparticles, and methods of their synthesis and use are described. Biological molecules labeled with the lipid nanoparticles, useful in bioaffinity assays with improved sensitivities are also described.

The present invention relates to a method for detecting specific proteins in amniotic fluid to predict the risk of preterm birth. The method determines different protein markers in premature amniotic fluid samples and normal amniotic fluid samples to predict the risk of preterm birth, and apply the expression levels of these protein markers to build a set of prediction models. This allows the medical staff to be prepared and greatly reduces the threat to the fetus.

The composition includes a first construct having a first portion of a protein and a first antigen-recognizing amino acid sequence; and a second construct having a second portion of the protein that catalyzes a reaction when combined with the first portion of the protein and a second antigen-recognizing amino acid sequence. The first and second synthetic constructs include a sulfhydryl group configured such that a disulfide bond is formed between the first and second synthetic constructs when the first antigen-recognizing amino acid sequence and the second antigen-recognizing amino acid sequence bind an antigen.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Some embodiments described herein relate to systems and methods operable to combine immunoassay and Total Protein techniques in a single sample run. Some embodiments described herein allow for multiple sequential immunoassays to be performed in the same microfluidic device. Some embodiments described herein relate to stripping reagents operable to remove primary antibodies associated with immunoassays. Such stripping reagents can allow for additional immunoassays and/or Total Protein assays to be performed on the same sample.